Ignite Creation Date:
2024-05-06 @ 6:55 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05839600
Status:
SUSPENDED
Last Update Posted:
2024-06-11
First Post:
2023-04-21
Brief Title:
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
An Open-label Phase I Dose Escalation and Expansion Trial to Investigate Safety and Efficacy of BI 1821736 in Patients With Advanced Solid Tumors
Status:
SUSPENDED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sponsor decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is open to adults with advanced solid tumours People with solid tumours for whom previous treatment was not successful or no treatment exists can take part
The purpose of this study is to find the highest dose of a medicine called BI 1821736 that people with advanced solid tumours can tolerate BI 1821736 is a type of immunotherapy It is a special virus that kills cancer cells and helps the immune system fight cancer In this study BI 1821736 is given to humans for the first time
Participants receive BI 1821736 as an infusion into a vein about every 3 weeks for up to 3 months Study doctors regularly check the participants health and monitor the tumours The doctors also take note of any unwanted effects that could have been caused by BI 1821736
The purpose of this study is to find the highest dose of a medicine called BI 1821736 that people with advanced solid tumours can tolerate BI 1821736 is a type of immunotherapy It is a special virus that kills cancer cells and helps the immune system fight cancer In this study BI 1821736 is given to humans for the first time
Participants receive BI 1821736 as an infusion into a vein about every 3 weeks for up to 3 months Study doctors regularly check the participants health and monitor the tumours The doctors also take note of any unwanted effects that could have been caused by BI 1821736
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2022-502125-17-00 | REGISTRY | None | None |
| U1111-1291-2873 | REGISTRY | WHO Registry | None |